Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Differential glycosylation in the envelope glycoprotein enhances DC-SIGN-mediated cell entry of the West African Ebolavirus Makona.

Created on 22 Sep 2026

Authors

Juan García-Bernalt Diego, Fátima Lasala, Joanna Luczkowiak, Clara Delaunay, María A Noriega, Oscar Malvar, Michel Thépaut, Gonzalo Rivas, Franck Fieschi, Ángeles Canales, José M Casasnovas, Rafael Delgado

Published in

Emerging microbes & infections. Volume 15. Issue 1. Pages 2732697. Epub Sep 22, 2026.

Abstract

During the 2013-2016 West African Ebola virus (EBOV) Makona epidemic, genomic surveillance identified an A82V substitution in the viral glycoprotein (GP) early in the outbreak. This mutation was associated with increased infectivity and faster viral spread, yet the host factors underlying this enhanced transmission remained unclear. Using a pseudotyped lentiviral system, we show that GP-A82V increases viral binding and infectivity in dendritic cells (DCs) and macrophages, key early and sustained target cells. This enhancement depends on expression of DC-SIGN, a lectin receptor on DCs. Filovirus-like particles carrying GP-V82 displayed accelerated infection kinetics in DC-SIGN-expressing cells. We identified two N-linked glycosylation sites, Ngly257 and Ngly563, that enhanced GP-V82 infectivity through simultaneous engagement of a DC-SIGN dimer. The A82V substitution increased soluble GP binding to DC-SIGN. Nuclear magnetic resonance analysis revealed enrichment of Lewis X (CD15), a known DC-SIGN ligand, in GP-V82. Blocking Lewis X with an anti-CD15 antibody reduced pseudovirus infection, confirming its functional role. These findings identify DC-SIGN as a key host factor contributing to EBOV Makona transmission and highlight viral envelope glycosylation as a mechanism facilitating viral adaptation and enhanced human-to-human spread.

PMID:
42770795
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement